Date: 2011-03-16
Type of information:
phase: 3
Announcement: completion of patient enrollment
Company: Agennix (Germany)
Product: talactoferrin
Action mechanism: Talactoferrin is an oral biologic therapy with immunomodulatory and antibacterial properties, which is being studied for the treatment of cancer and severe sepsis.
Disease: non-small cell lung cancer
Therapeutic area: Cancer - Oncology
Country:
Trial
details: The FORTIS-M trial is a global randomized, double-blind trial evaluating talactoferrin plus best supportive care compared to placebo plus best supportive care in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following two or more prior treatment regimens. The study enrolled 742 patients at over 160 sites globally.
Latest
news: Agennix has announced the completion of patient enrollment in the talactoferrin FORTIS-M Phase III registration trial. The Company also provided an update on the anticipated availability of topline data from the FORTIS-M trial. Agennix now expects to see these data in the first half of 2012.
